Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.30 |
| ▸ | PRCP | P42785 | 2/20 | 0.36 |
| ▸ | OTC | P00480 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 3/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.33 |
| ▸ | GLI1 | P08151 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GSR | P00390 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL1675364 | 0.97 | PRCP (0.38) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL29164461 | 0.97 | PRCP (0.38) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL28774540 | 0.97 | PRCP (0.38) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL4807560 | 0.97 | PRCP (0.38) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL3087368 | 0.97 | PRCP (0.38) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL1417757 | 0.97 | PRCP (0.38) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL8582228 | 0.97 | PRCP (0.38) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL8697426 | 0.97 | PRCP (0.38) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL28470370 | 0.94 | PRCP (0.38) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL6535144 | 0.93 | PRCP (0.37) | PRCPOTCNOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11752242-B2 | Medical devices, systems, and methods utilizing antithrombin-heparin composition | ATH THERAPEUTICS INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20180177924-A1 | Medical Devices, Systems, and Methods Utilizing Antithrombin-Heparin Composition | ATTWILL Medical Solution Inc. (CA) | 2018-06-28 | — | — | US | disclosed |
| WO-2016201202-A1 | MEDICAL DEVICES, SYSTEMS, AND METHODS UTILIZING ANTITHROMBIN-HEPARIN COMPOSITIONS | ATTWILL MEDICAL SOLUTIONS INC. (CA) | 2016-12-15 | — | — | WO | disclosed |
| US-9429561-B2 | Detection of nucleic acid lesions and adducts using nanopores | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150185200-A1 | DETECTION OF NUCLEIC ACID LESIONS AND ADDUCTS USING NANOPORES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-02 | — | — | US | disclosed |
| US-9005425-B2 | Detection of nucleic acid lesions and adducts using nanopores | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2015-04-14 | — | — | US | disclosed |
| US-20120091005-A1 | DETECTION OF NUCLEIC ACID LESIONS AND ADDUCTS USING NANOPORES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-04-19 | — | — | US | disclosed |
| WO-2011109825-A2 | DETECTION OF NUCLEIC ACID LESIONS AND ADDUCTS USING NANOPORES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11752242-B2 | Medical devices, systems, and methods utilizing antithrombin-heparin composition | SERPINC1, HPSE, PLAT | ACE 277/4885PRCP 727/4885OTC 3110/4885 |
| US-20180177924-A1 | Medical Devices, Systems, and Methods Utilizing Antithrombin-Heparin Composition | SERPINC1, HPSE, PLAT | ACE 277/4885PRCP 727/4885OTC 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.